Cisplatin versus carboplatin as adjuvant chemotherapy for completely resected non-small cell lung cancer: a multicenter retrospective cohort study
Surgery Today · 2026-10 · 56 (10) · 2370-2377
DOI: 10.1007/s00595-026-03375-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Surgery Today, online erschienen am 18.06.2026. Verfasst von Masatsugu Hamaji und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, 634-8511, Nara, Japan. mhamaji@kuhp.kyoto-u.ac.…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carboplatin, Carcinoma, Non-Small-Cell Lung, Cisplatin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: The current guidelines recommend cisplatin-based adjuvant chemotherapy for patients with completely resected stage II-III non-small cell lung cancer (NSCLC). Carboplatin-based chemotherapy is occasionally selected, although there is limited evidence of its long-term outcomes. We conducted this study to compare the long-term outcomes of cisplatin- based chemotherapy with those of carboplatin-based chemotherapy. METHODS: A retrospective chart review was performed to identify patients aged ≥ 18 years with performance status 0-1, complete resection, and pathological stage II-IIIA NSCLC (7th edition) between 2014 and 2016 in our multi-institutional database. Patients were classified into two groups: the cisplatin-based adjuvant chemotherapy group and the carboplatin-based adjuvant chemotherapy group. To adjust for baseline differences, inverse probability of treatment weighting (IPTW) based on propensity scores was applied. The primary outcome was recurrence-free survival (RFS) and the secondary outcomes were cancer-specific survival (CSS) and overall survival (OS). RESULTS: A total 342 patients were included, of whom 195 received cisplatin-based adjuvant chemotherapy and 147 received carboplatin-based chemotherapy. After IPTW adjustment, the hazard ratios for RFS, CSS, and OS were 1.10 (95% confidence interval [CI]: 0.82-1.49, p = 0.526), 1.11 (95% CI: 0.68-1.82, p = 0.675), and 1.46 (95% CI: 0.96-2.22, p = 0.08), respectively. CONCLUSIONS: Carboplatin-based adjuvant chemotherapy may be considered for selected patients deemed unfit to receive cisplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, 634-8511, Nara, Japan. mhamaji@kuhp.kyoto-u.ac.jp.
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, 634-8511, Nara, Japan.
- Institute for Clinical and Translational Science, Nara Medical University, Kashihara, Japan.
- Division of Thoracic surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
- Department of Thoracic Surgery, Kyoto University, Kyoto, Japan.
- Department of Thoracic Surgery, Otsu Red Cross Hospital, Shiga, Japan.
Zitieren
APA
Hamaji, M., Miyata, R., Takeuchi, J., Ozu, N., Kohama, T., Sumitomo, R., Takahashi, M., Fukada, T., Kobayashi, M., Kumaya, Y., & Chen-Yoshikawa, T. F. (2026). Cisplatin versus carboplatin as adjuvant chemotherapy for completely resected non-small cell lung cancer: a multicenter retrospective cohort study. Surgery Today, 56(10), 2370-2377. https://doi.org/10.1007/s00595-026-03375-0
Vancouver
Hamaji M, Miyata R, Takeuchi J, Ozu N, Kohama T, Sumitomo R, et al. Cisplatin versus carboplatin as adjuvant chemotherapy for completely resected non-small cell lung cancer: a multicenter retrospective cohort study. Surgery Today. 2026;56(10):2370-2377. doi:10.1007/s00595-026-03375-0
BibTeX
@article{Hamaji2026,
author = {Hamaji, Masatsugu and Miyata, Ryo and Takeuchi, Jiro and Ozu, Naoki and Kohama, Takuya and Sumitomo, Ryota and Takahashi, Mamoru and Fukada, Takehisa and Kobayashi, Megumi and Kumaya, Yosuke and Chen-Yoshikawa, Toyofumi Fengshi},
title = {Cisplatin versus carboplatin as adjuvant chemotherapy for completely resected non-small cell lung cancer: a multicenter retrospective cohort study},
journal = {Surgery Today},
year = {2026},
volume = {56},
number = {10},
pages = {2370--2377},
doi = {10.1007/s00595-026-03375-0}
}
EUVIMED